771 related articles for article (PubMed ID: 28826571)
41. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
Aardoom MA; Veereman G; de Ridder L
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126015
[TBL] [Abstract][Full Text] [Related]
42. Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study.
Ma C; Beilman CL; Huang VW; Fedorak DK; Wong K; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
Can J Gastroenterol Hepatol; 2016; 2016():2079582. PubMed ID: 27478817
[TBL] [Abstract][Full Text] [Related]
43. Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States.
Sandborn WJ; Sakuraba A; Wang A; Macaulay D; Reichmann W; Wang S; Chao J; Skup M
Curr Med Res Opin; 2016 Jul; 32(7):1233-41. PubMed ID: 26986449
[TBL] [Abstract][Full Text] [Related]
44. Short-term response to adalimumab in childhood inflammatory bowel disease.
Noe JD; Pfefferkorn M
Inflamm Bowel Dis; 2008 Dec; 14(12):1683-7. PubMed ID: 18618629
[TBL] [Abstract][Full Text] [Related]
45. Real-World Incidence of Suboptimal Response to Anti-Tumor Necrosis Factor Therapy for Ulcerative Colitis: A Nationwide Population-Based Study.
Shin JY; Park HM; Lee MY; Jeon JY; Yoo HJ; Ye BD
Gut Liver; 2021 Nov; 15(6):867-877. PubMed ID: 33785664
[TBL] [Abstract][Full Text] [Related]
46. Long-term assessment of clinical response to adalimumab therapy in refractory ulcerative colitis.
Hussey M; Mc Garrigle R; Kennedy U; Holleran G; Kevans D; Ryan B; Breslin N; Mahmud N; McNamara D
Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):217-21. PubMed ID: 26587866
[TBL] [Abstract][Full Text] [Related]
47. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM
Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161
[TBL] [Abstract][Full Text] [Related]
48. Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.
Eberl A; Huoponen S; Pahikkala T; Blom M; Arkkila P; Sipponen T
Scand J Gastroenterol; 2017 Dec; 52(12):1348-1353. PubMed ID: 28838273
[TBL] [Abstract][Full Text] [Related]
49. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
50. Treatment Patterns and Sequencing in Patients With Inflammatory Bowel Disease.
Brady JE; Stott-Miller M; Mu G; Perera S
Clin Ther; 2018 Sep; 40(9):1509-1521.e5. PubMed ID: 30126706
[TBL] [Abstract][Full Text] [Related]
51. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results.
Argüelles-Arias F; Guerra Veloz MF; Perea Amarillo R; Vilches-Arenas A; Castro Laria L; Maldonado Pérez B; Chaaro Benallal D; Benítez Roldán A; Merino V; Ramirez G; Calleja-Hernández MA; Caunedo Álvarez A; Romero Gómez M
Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1290-1295. PubMed ID: 28902041
[TBL] [Abstract][Full Text] [Related]
52. Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis.
Kennedy NA; Warner B; Johnston EL; Flanders L; Hendy P; Ding NS; Harris R; Fadra AS; Basquill C; Lamb CA; Cameron FL; Murray CD; Parkes M; Gooding I; Ahmad T; Gaya DR; Mann S; Lindsay JO; Gordon J; Satsangi J; Hart A; McCartney S; Irving P; ; Lees CW
Aliment Pharmacol Ther; 2016 Apr; 43(8):910-923. PubMed ID: 26892328
[TBL] [Abstract][Full Text] [Related]
53. Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation.
Taxonera C; Iglesias E; Muñoz F; Calvo M; Barreiro-de Acosta M; Busquets D; Calvet X; Rodríguez A; Pajares R; Gisbert JP; López-Serrano P; Pérez-Calle JL; Ponferrada Á; De la Coba C; Bermejo F; Chaparro M; Olivares D; Alba C; Fernández-Blanco I
Dig Dis Sci; 2017 Feb; 62(2):481-490. PubMed ID: 27995400
[TBL] [Abstract][Full Text] [Related]
54. Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation.
Viazis N; Koukouratos T; Anastasiou J; Giakoumis M; Triantos C; Tsolias C; Theocharis G; Karamanolis DG
Eur J Gastroenterol Hepatol; 2015 Apr; 27(4):436-41. PubMed ID: 25874518
[TBL] [Abstract][Full Text] [Related]
55. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
56. Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study.
Murthy SK; Begum J; Benchimol EI; Bernstein CN; Kaplan GG; McCurdy JD; Singh H; Targownik L; Taljaard M
Gut; 2020 Feb; 69(2):274-282. PubMed ID: 31196874
[TBL] [Abstract][Full Text] [Related]
57. Polygenetic risk scores do not add predictive power to clinical models for response to anti-TNFα therapy in inflammatory bowel disease.
Karmi N; Bangma A; Spekhorst LM; van Dullemen HM; Visschedijk MC; Dijkstra G; Weersma RK; Voskuil MD; Festen EAM
PLoS One; 2021; 16(9):e0256860. PubMed ID: 34534227
[TBL] [Abstract][Full Text] [Related]
58. Efficacies of first and second tumor necrosis factor inhibitors in refractory ulcerative colitis patients in real-world practice.
Marutani Y; Mizoshita T; Sugiyama T; Togawa S; Katano T; Yamada T; Hirata Y; Kimura Y; Miyaki T; Inoue Y; Suzuki E; Sasaki M; Kataoka H
Indian J Gastroenterol; 2020 Dec; 39(6):565-575. PubMed ID: 33106991
[TBL] [Abstract][Full Text] [Related]
59. Impact of antitumour necrosis factor therapy on surgery in inflammatory bowel disease: a population-based study.
Hawthorne AB; Arms-Williams B; Cannings-John R; Pollok RCG; Berry A; Harborne P; Trivedi A
BMJ Open Gastroenterol; 2024 May; 11(1):. PubMed ID: 38777566
[TBL] [Abstract][Full Text] [Related]
60. Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.
Singh N; Rabizadeh S; Jossen J; Pittman N; Check M; Hashemi G; Phan BL; Hyams JS; Dubinsky MC
Inflamm Bowel Dis; 2016 Sep; 22(9):2121-6. PubMed ID: 27542130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]